As of Aug 23
| -0.43 / -0.82%|
The 26 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 54.51, with a high estimate of 66.96 and a low estimate of 33.17. The median estimate represents a +4.29% increase from the last price of 52.27.
The current consensus among 27 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.